Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
558 Programmed death (PD)-1 and PD-ligand-1 inhibitors in the treatment of non-small cell lung cancer: a systematic review of their efficacy and safety
Compose a Response to This Article
Other responses
No responses have been published for this article.
